Jacqueline Claudia Barrientos, MD
Chronic lymphocytic leukemia (CLL) is entering a new age of combination therapy, according to Jacqueline C. Barrientos, MD.
, Barrientos, an associate professor at the Feinstein Institute for Medical Research at Northwell Health, discussed these combinations trials, as well as emerging agents in the CLL pipeline.
OncLive: Can you discuss the impact of recent combination trials in CLL?
We are trying to get deeper responses than what we have seen with regular use of a B-cell receptor signaling agent. Moving forward, data such as from the TAP CLARITY trial presented by the UK group during the 2017 ASH Annual Meeting, is going to be very important. This trial evaluated ibrutinib in combination with venetoclax in patients with relapsed/refractory CLL. There was no increase in toxicity with the combination, while achieving deep responses. The MRD negativity in the patients who had more than 6 cycles was unbelievable, and many of the patients showed no evidence of disease in the peripheral blood or in the bone marrow. Additionally, many of them achieved complete remission, which is unheard of in patients taking ibrutinib as monotherapy.
People older than 65 don’t traditionally do well with a chemotherapy regimen like fludarabine, cyclophosphamide, and rituximab (FCR), and now have the opportunity to benefit from combination therapy. Even patients in their 80s can receive these regimens. It is clearly changing the natural evolution of the disease. We can now treat our patients with high-risk disease that otherwise would not respond very well to chemotherapy. There is a possibility of a future full of chemotherapy-free regimens for our patients, and it will provide the opportunity for our patients to achieve deeper responses, so they do not have to be on a drug indefinitely.
What population of patients are best suited to receive ibrutinib as a single agent as opposed to in combination?
I believe that the perfect candidate for ibrutinib monotherapy is a patient who is over 65. Ibrutinib is a drug that must be taken continuously, so if it is given in the frontline or relapsed/refractory setting to a younger patient, it might expose that patient to long-term toxicities, such as hypertension, arthritis, bleeding events, and arrhythmias.
In high-risk disease, different clinical trials are showing that patients with 17p deletion are the ones who will relapse the earliest, even though they initially respond beautifully. Combination strategies would be best for these patients. There are many clinical trials currently evaluating the role of combinations in this high-risk patient group.
... to read the full story